TRANSFERRIN-REZEPTOR-TRANSGENE MODELLEN

European patent · EP3583118 · In force

Register entry

Publication number
EP3583118
Application number
EP18711190
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 15, 2018
Published
Dec 25, 2019
Granted
Jun 11, 2025
Protection ends at the latest
Feb 14, 2038
Next annual fee due
Feb 28, 2027
IPC classes
A01K 67/0275 (2024.01)
C07K 14/705 (2006.01)
G01N 33/68 (2006.01)
C12N 5/10 (2006.01)
C12N 15/63 (2006.01)
Priority
US 201762460692 P 17.02.2017
US 201762543658 P 10.08.2017
US 201762543559 P 10.08.2017
US 201762583314 P 08.11.2017
PCT application
PCT/US2018/018302 15.02.2018
PCT publication
WO2018/152285 23.08.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 23, 2026

    Change

    Published in Swissreg on 23.04.2026

  2. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  3. Jul 8, 2025

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach, 8027 Zürich

    Published in Swissreg on 08.07.2025

  4. Jun 11, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 11.06.2025

Parties

Holder

Denali Therapeutics Inc.

161 Oyster Point Boulevard, South San Francisco, California 94080, US

Agent

Isler & Pedrazzini AG

Postfach, 8027 Zürich

Inventor

DENNIS, Mark S.

South San Francisco California 94080, US

SILVERMAN, Adam P.

South San Francisco California 94080, US

ZUCHERO, Joy Yu

South San Francisco California 94080, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.